| abstract |
An objective of the present invention is to provide novel therapeutic agents for non-immediate-type allergic diseases that comprise, as an active ingredient, a cannabinoid receptor modulator, particularly that selectively acts on peripheral cell type cannabinoid receptors (CB2), and more particularly an inverse agonist. n The present invention provides therapeutic agents for non-immediate-type allergic diseases which comprises a cannabinoid receptor modulator, particularly an inverse agonist that selectively acts on peripheral cell type cannabinoid receptors, specifically N-(benzo[1,3]dioxol-5-yl methyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide or such, or pharmaceutically acceptable salt thereof. The therapeutic agents of the present invention are effective, for example, against intractable allergic diseases, such as asthma and atopic dermatitis. |